Literature DB >> 9600640

Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells.

T P Zucker1, D Bönisch, A Hasse, T Grosser, A A Weber, K Schrör.   

Abstract

This study compares the antimitogenic effects of iloprost and prostaglandin E1 on platelet-derived growth factor-BB stimulated DNA synthesis ([3H]thymidine incorporation) in bovine coronary artery smooth muscle cells. When added 20-24 h after stimulation with platelet-derived growth factor-BB (20 ng/ml), both iloprost and prostaglandin E1, concentration-dependently (IC50 3-5 nM) inhibited DNA synthesis. However, when added together with the growth factor (0-24 h), the inhibition of DNA synthesis by iloprost was markedly attenuated, indicating tolerance development. In contrast, no tolerance to antimitogenic effects of prostaglandin E1 or forskolin were observed. When added to iloprost-tolerant cells, both prostaglandin E1 and forskolin, still inhibited DNA synthesis. There was no evidence for transcriptional down-regulation of prostacyclin receptor gene by iloprost. The data demonstrate a tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 and suggest that the receptors, mediating the antiproliferative actions of these prostaglandins, may be different.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600640     DOI: 10.1016/s0014-2999(98)00022-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Regulation of prostacyclin and prostaglandin E(2) receptor mediated responses in adult rat dorsal root ganglion cells, in vitro.

Authors:  D K Rowlands; C Kao; H Wise
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Prostacyclin receptor regulation--from transcription to trafficking.

Authors:  C Midgett; J Stitham; K A Martin; J Hwa
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

3.  Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells.

Authors:  E Bretschneider; R Kaufmann; M Braun; G Nowak; E Glusa; K Schrör
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism.

Authors:  Koji Ohashi; Noriyuki Ouchi; Kaori Sato; Akiko Higuchi; Tomo-o Ishikawa; Harvey R Herschman; Shinji Kihara; Kenneth Walsh
Journal:  Mol Cell Biol       Date:  2009-04-27       Impact factor: 4.272

Review 5.  Expression profiling of cardiovascular disease.

Authors:  Stephen Archacki; Qing Wang
Journal:  Hum Genomics       Date:  2004-08       Impact factor: 4.639

Review 6.  Inhaled treprostinil and pulmonary arterial hypertension.

Authors:  Samuel T Nadler; Jeffrey D Edelman
Journal:  Vasc Health Risk Manag       Date:  2010-12-03

7.  Prostacyclin: an inflammatory paradox.

Authors:  Jeremiah Stitham; Charles Midgett; Kathleen A Martin; John Hwa
Journal:  Front Pharmacol       Date:  2011-05-13       Impact factor: 5.810

8.  Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs.

Authors:  Ralph T Schermuly; Soni S Pullamsetti; Susanne C Breitenbach; Norbert Weissmann; Hossein A Ghofrani; Friedrich Grimminger; Sigrid M Nilius; Karsten Schrör; Jutta M Kirchrath; Werner Seeger; Frank Rose
Journal:  Respir Res       Date:  2007-01-26

9.  Immature and mature species of the human Prostacyclin Receptor are ubiquitinated and targeted to the 26S proteasomal or lysosomal degradation pathways, respectively.

Authors:  Peter D Donnellan; B Therese Kinsella
Journal:  J Mol Signal       Date:  2009-09-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.